JAZZ vs. JNJ: Jazz Pharmaceuticals vs. Johnson & Johnson Stock Comparison

November 11, 2026

How do Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Profile Item	JAZZ	JNJ
Name	Jazz Pharmaceuticals plc	Johnson & Johnson
Country/Region	Ireland	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	15.07 billion USD	664.95 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 1, 2007	January 2, 1962
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

JAZZ

JNJ

GSPC

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Total Return (1Y)	84.44%	53.82%
Total Return (3Y, Annualized)	27.57%	27.51%
Total Return (5Y, Annualized)	12.88%	14.71%

Risk Profile

Drawdown History

JAZZ

JNJ

GSPC

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Volatility (1Y, Annualized)	38.74%	21.23%
Beta (5Y)	0.33	0.21
Max Drawdown (5Y)	-42.03%	-18.41%
Avg. Volume (3M)	878.80K	6.93M

Risk-Adjusted Performance

Risk-Return Positioning

JAZZ and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Sharpe Ratio (1Y)	2.07	2.33
Sortino Ratio (1Y)	4.14	3.66

Profitability

ROE (TTM)

Johnson & Johnson (JNJ) at 20.02% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for JNJ.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.05%

Max: 109.18%
Q3: 6.23%
JAZZ: 5.05%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 109.18%
JNJ: 20.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Johnson & Johnson (JNJ) at 16.20% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.37%

Max: 18.05%
Q3: 4.78%
JAZZ: 4.37%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max: 18.05%
JNJ: 16.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.17%

Max: 83.12%
JAZZ: 30.17%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 83.12%
JNJ: 25.74%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
ROE (TTM)	5.05%	20.02%
ROA (TTM)	6.92%	8.46%
Net Margin (TTM)	4.37%	16.20%
Operating Margin (TTM)	30.17%	25.74%
Gross Margin (TTM)	91.10%	67.78%

Growth

Revenue Growth

Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Jazz Pharmaceuticals (JAZZ) at -167.51% is in the bottom quartile, showing a clear gap in earnings momentum.

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Revenue Growth (YoY)	4.88%	6.05%
Revenue Growth (3Y CAGR)	5.26%	5.60%
EPS Growth (YoY)	-167.51%	90.50%
EPS Growth (3Y CAGR)	--	17.90%

Financial Strength

Current Ratio (MRQ)

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.82

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JAZZ: 1.82
Min: 0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JNJ: 1.02
Min: 0.10

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.55 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 1.42
JAZZ: 1.35
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max: 1.42
Q3: 0.65
JNJ: 0.55
Median: 0.15
Q1: 0.02
Min: 0.00

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Current Ratio (MRQ)	1.82	1.02
Debt / Equity (MRQ)	1.35	0.55
Net Debt / EBITDA	1.39	0.79

Dividends

Dividend Yield (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ: 80.12%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
Dividend Yield (TTM)	0.00%	1.94%
Dividend Payout Ratio (TTM)	0.00%	80.12%

Valuation

P/E Ratio (TTM)

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

69.46

Max: 85.34
JAZZ: 69.46
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max: 85.34
Q3: 43.46
JNJ: 41.92
Median: 26.69
Q1: 13.30
Min: 0.07

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.19

Max: 58.18
Q3: 25.77
Median: 7.30
JAZZ: 3.19
Q1: 3.01
Min: 0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 58.18
Q3: 25.77
Median: 7.30
JNJ: 6.69
Q1: 3.01
Min: 0.01

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.59

Max: 13.53
Q3: 6.54
JAZZ: 3.59
Median: 3.25
Q1: 1.69
Min: -5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 13.53
JNJ: 8.16
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Jazz Pharmaceuticals (JAZZ) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Jazz Pharmaceuticals (JAZZ) and Johnson & Johnson (JNJ)
Metric	JAZZ	JNJ
P/E Ratio (TTM)	69.46	41.92
P/S Ratio (TTM)	3.19	6.69
P/B Ratio (MRQ)	3.59	8.16
Free Cash Flow Yield (TTM)	11.16%	2.78%